Peptidylproline cis/trans isomerases A Galat, SM Metcalfe Progress in biophysics and molecular biology 63 (1), 67-118, 1995 | 313 | 1995 |
Delivering the power of nanomedicine to patients today M Germain, F Caputo, S Metcalfe, G Tosi, K Spring, AKO Åslund, A Pottier, ... Journal of Controlled Release 326, 164-171, 2020 | 277 | 2020 |
Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW) S Cobbold, SU Metcalfe Tissue antigens 43 (3), 137-154, 1994 | 269 | 1994 |
AMPLIFICATION OF NATURAL REGULATORY IMMUNE MECHANISMS FOR TRANSPLANTATION TOLERANCE1 ZK Chen, SP Cobbold, H Waldmann, S Metcalfe Transplantation 62 (9), 1200-1206, 1996 | 196 | 1996 |
Mesenchymal stem cells and management of COVID-19 pneumonia SM Metcalfe Medicine in drug discovery 5, 100019, 2020 | 179 | 2020 |
Genetic control of IL‐1β bioactivity through differential regulation of the IL‐1 receptor antagonist J Vamvakopoulos, C Green, S Metcalfe European journal of immunology 32 (10), 2988-2996, 2002 | 160 | 2002 |
Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6 W Gao, L Thompson, Q Zhou, P Putheti, TM Fahmy, TB Strom, ... Cell Cycle 8 (9), 1444-1450, 2009 | 157 | 2009 |
Tolerance in the mouse to major histocompatibility complex‐mismatched heart allografts, and to rat heart xenografts, using monoclonal antibodies to CD4 and CD8 Z Chen, S Cobbold, S Metcalfe, H Waldmann European journal of immunology 22 (3), 805-810, 1992 | 153 | 1992 |
Mutational Biosynthesis of Novel Rapamycins by a Strain of Streptomyces hygroscopicus NRRL 5491 Disrupted inrapL, Encoding a Putative Lysine Cyclodeaminase LE Khaw, GA Böhm, S Metcalfe, J Staunton, PF Leadlay Journal of bacteriology 180 (4), 809-814, 1998 | 140 | 1998 |
Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery J Park, W Gao, R Whiston, TB Strom, S Metcalfe, TM Fahmy Molecular pharmaceutics 8 (1), 143-152, 2011 | 137 | 2011 |
Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF) S Rittchen, A Boyd, A Burns, J Park, TM Fahmy, S Metcalfe, A Williams Biomaterials 56, 78-85, 2015 | 126 | 2015 |
LIF in the regulation of T-cell fate and as a potential therapeutic SM Metcalfe Genes & Immunity 12 (3), 157-168, 2011 | 117 | 2011 |
Cyclosporine, FK506, and rapamycin: some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells SM METCALFE, FM RICHARDS Transplantation 49 (4), 798-802, 1990 | 112 | 1990 |
The phosphorylation status of Ascl1 is a key determinant of neuronal differentiation and maturation in vivo and in vitro FR Ali, K Cheng, P Kirwan, S Metcalfe, FJ Livesey, RA Barker, A Philpott Development 141 (11), 2216-2224, 2014 | 105 | 2014 |
Cyclosporine does not prevent cytoplasmic calcium changes associated with lymphocyte activation S Metcalfe Transplantation 38 (2), 161-164, 1984 | 81 | 1984 |
The interleukin‐1 receptor antagonist gene: a single‐copy variant of the intron 2 variable number tandem repeat (VNTR) polymorphism JE Vamvakopoulos, CJ Taylor, GJ Morris‐Stiff, C Green, S Metcalfe European journal of immunogenetics 29 (4), 337-340, 2002 | 78 | 2002 |
The interaction of p53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage AL Okorokov, CP Rubbi, S Metcalfe, J Milner Oncogene 21 (3), 356-367, 2002 | 74 | 2002 |
Immuno-isolation of pancreatic islet allografts using pegylated nanotherapy leads to long-term normoglycemia in full MHC mismatch recipient mice H Dong, TM Fahmy, SM Metcalfe, SL Morton, X Dong, L Inverardi, ... PloS one 7 (12), e50265, 2012 | 71 | 2012 |
New rapamycin derivatives by precursor-directed biosynthesis P Lowden, GA Böhm, S Metcalfe, J Staunton, PF Leadlay ChemBioChem 5 (4), 535-538, 2004 | 71 | 2004 |
Wild-type p53 protein shows calcium-dependent binding to F-actin S Metcalfe, A Weeds, AL Okorokov, J Milner, M Cockman, B Pope Oncogene 18 (14), 2351-2355, 1999 | 61 | 1999 |